Skip to main navigation Skip to search Skip to main content

Surgical treatment of valvular heart disease in patients with acromegaly

  • D. G. Cable
  • , J. A. Dearani
  • , T. O'Brien
  • , T. A. Orszulak
  • , F. J. Puga
  • , H. V. Schaff
  • Mayo Clinic

Research output: Contribution to a Journal (Peer & Non Peer) › Article › peer-review

10 Citations (Scopus)

Abstract

Background and aim of the study: Acromegaly is associated with heart disease in one-third of patients, and diastolic dysfunction may precede global systolic dysfunction. Patients with acromegalic heart disease may have valvular disease, but the role of surgery in such patients has not been established. The purpose of this study was to document the outcome of surgery in a series of these patients from one institution. Methods: Among 951 patients with the diagnosis of acromegaly seen at our institution since 1972, 10 (eight men, two women) have undergone operation for valvular heart disease. Average patient age was 62.2 ± 11.5 years; average body weight was 84 ± 13 kg; average height was 178 ± 12 cm. The mean duration of acromegaly was 15.2 ± 12.7 years. At the time of heart surgery, seven patients had active disease, defined by elevation of growth hormone levels, while three had inactive disease. Treatment of pituitary adenomas before valvular surgery included surgical resection in three patients and external-beam radiation treatment in four. The preoperative ejection fraction was 42 ± 19% (range: 20% to 66%). Valve lesions included aortic stenosis in four patients, aortic regurgitation in four, and mitral regurgitation in three (one patient had double valve disease). Results: Valve replacement was performed in all patients with aortic disease (two bioprostheses, six mechanical), and three patients with mitral regurgitation had repair. Concomitant procedures performed in seven patients included coronary bypass (two), left ventricular aneurysmectomy (two), and ligation of the left atrial appendage, septal myectomy and defibrillator insertion (one each). Early complications included endocarditis, low cardiac output and arrhythmia in one patient each. There were no perioperative deaths. One patient underwent reoperation ten years later for a perivalvular leak. Conclusion: Valvular surgery can be performed safely in acromegalic patients, even those with active endocrinopathy.

Original languageEnglish
Pages (from-to)828-831
Number of pages4
JournalJournal of Heart Valve Disease
Volume9
Issue number6
Publication statusPublished - 2000
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Surgical treatment of valvular heart disease in patients with acromegaly'. Together they form a unique fingerprint.

Cite this